- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT00561496
Pharmacokinetic Study of the Vaginal Microbicide Agent 1% Tenofovir Gel
Single Dose and 14-Day Once or Twice-Daily Pharmacokinetic Study of the Vaginal Microbicide Agent 1% Tenofovir Gel
This is a multi-center, pharmacokinetic study involving a single-dose phase, a wash out phase and a two-week once or twice-daily dosing phase for each of 49 volunteers.
In the single-dose phase, each volunteer will apply the single dose in the clinic. Participants will be randomized to have cervicovaginal samples and biopsies collected at one of seven time-points [0.5, 1, 2, 4, 6, 8, and 24 hour(s)] after the single-dose. Blood samples will be drawn at 0.5, 1, 2, 4, 6, 8, and 24 hour(s) after the single-dose.
In the two-week phase, the study supplies will be distributed and the participants will be randomized to apply each dose either once or twice-daily for two weeks. At the one week follow-up visit a blood sample will be drawn prior to the morning dose to obtain a trough value and cervicovaginal samples will be collected four hours after the morning dose. At the two week follow-up visit blood samples will be drawn prior to the morning dose to obtain a trough value and then at 0.5, 1, 2, 4, 6, 8, and 24 hour(s) from the final morning dose. Participants will be randomized to have cervicovaginal samples and biopsies collected at either 4, 8 or 24 hours after the final morning dose.
Up to 10 participants who have completed the first two phases of the study, will be asked to participate in a third phase to have cervicovaginal samples, biopsies and blood samples collected 12 hours after a single-dose.
연구 개요
연구 유형
등록 (실제)
단계
- 1단계
연락처 및 위치
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Must be between 18-45 years old, inclusive
- Must be in general good health by volunteer history without any clinically significant systemic disease (including liver disease/hepatitis, gastrointestinal disease, kidney disease, thyroid disease, osteoporosis or bone disease)
- Must have regular menstrual cycles (minimum of 26 and maximum of 38 days)
- Must be at least 2 months since last pregnancy outcome and have had at least two spontaneous menses
- Must abstain from sexual activity and use of intravaginal products for 72 hours prior to the start of the single-dose phase and multi-dose phase, for at least one week following vaginal biopsies and for the duration of the study phases
- Willingness to give voluntary consent, sign an informed consent form and comply with study procedures as required by the protocol
Exclusion Criteria:
- Currently pregnant or at risk for pregnancy (may be using Paragard® IUD, effective barrier method, female sterilization or abstinence, or be sexually active with a vasectomized partner)
- Currently breastfeeding or planning to breastfeed during the course of the study
- Use of any hormonal contraceptives within 30 days of enrollment
- Use of Depo-Provera within 120 days of enrollment History of abnormal Pap smear (by volunteer history) that has not been evaluated and treated, if indicated, according to standard guidelines
- Current vaginal or urinary tract infection
- Positive test for Neisseria gonorrhea or Chlamydia trachomatis at the time of screening
- Positive wet mount for Trichomonas vaginalis at the time of screening or enrollment
- Deep epithelial genital findings such as abrasions, ulcerations, and lacerations, or vesicles suspicious for a sexually transmitted infection
- Current or past use of any anti-retroviral therapies including but not limited to systemic tenofovir (Viread®)
- Current or recent drug or alcohol abuse
- Current or anticipated use of drugs on a daily basis that may reduce renal function (e.g. acyclovir or ibuprofen) or liver function (e.g. tylenol)
- HIV positive at the time of screening
- Hepatitis B surface antigen (HBsAg) positive at the time of screening
- Grade 1 or higher serum chemistry or complete blood count abnormality in accordance with DAIDS toxicity table values
- Abnormal finding on laboratory or physical examination or a medical condition which, in the opinion of the investigator, would make participation in the study unsafe or would complicate interpretation of data
- Participation in any other research study in the 30 days prior to screening and/or plans to participate in any other research study during entire study duration
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 기초 과학
- 할당: 해당 없음
- 중재 모델: 단일 그룹 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
---|---|
다른: Twice daily
Tenofovir gel intravaginal twice daily for 14 days
|
Intravaginal (4grams)single dose followed by fourteen days
다른 이름들:
|
다른: Once daily
Tenofovir gel intravaginal once daily for 14 days
|
Intravaginal (4grams)single dose followed by fourteen days
다른 이름들:
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
기간 |
---|---|
Concentration of tenofovir in local genital tract compartments (intraluminal, mononuclear cells and vaginal tissue levels). Concentration (Cmax) and time of maximum concentration (Tmax) of tenofovir in the systemic compartment.
기간: Single dose; two weeks (after once or twice-daily vaginal administration)
|
Single dose; two weeks (after once or twice-daily vaginal administration)
|
공동 작업자 및 조사자
스폰서
수사관
- 연구 책임자: Jill Schwartz, MD, CONRAD
간행물 및 유용한 링크
연구 기록 날짜
연구 주요 날짜
연구 시작
기본 완료 (실제)
연구 완료 (실제)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (추정)
연구 기록 업데이트
마지막 업데이트 게시됨 (추정)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
키워드
추가 관련 MeSH 약관
기타 연구 ID 번호
- A04-095
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .
HIV 감염에 대한 임상 시험
-
Hospital Clinic of Barcelona완전한
-
CDC FoundationGilead Sciences알려지지 않은
-
University of WashingtonNational Institute of Mental Health (NIMH)모병
-
University of Minnesota빼는HIV 감염 | HIV/에이즈 | 에이즈 | 보조기구 | 에이즈/HIV 문제 | 에이즈와 감염미국
-
French National Agency for Research on AIDS and...Elizabeth Glaser Pediatric AIDS Foundation완전한파트너 HIV 테스트 | 부부 에이즈 상담 | 커플커뮤니케이션 | HIV 발병률카메룬, 도미니카 공화국, 그루지야, 인도
-
Michael HoelscherClinton Health Access Initiative Inc.; Instituto Nacional de Saúde (INS), Ministério da... 그리고 다른 협력자들모집하지 않고 적극적으로HIV, 신생아 HIV 조기 진단(EID), 현장 진료 검사(PoC)모잠비크, 탄자니아
-
Allegheny Singer Research Institute (also known...모집하지 않고 적극적으로
-
National Institute of Allergy and Infectious Diseases...Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)완전한
-
Erasmus Medical Center모병
-
Erasmus Medical Center모집하지 않고 적극적으로
Tenofovir gel에 대한 임상 시험
-
National Taiwan University Hospital알려지지 않은
-
University Hospital Southampton NHS Foundation...Vascular Solutions LLC완전한
-
Mentor Worldwide, LLC완전한
-
Rabin Medical Center알려지지 않은
-
Geneve TEAM AmbulancesUniversity Hospital, Geneva; ESAMB - College of Higher Education in Ambulance Care; Ambulances...완전한
-
Seoul National University Hospital완전한
-
Geneve TEAM AmbulancesService de protection et sauvetage Lausanne (SPSL), Emergency Medical Services, Switzerland 그리고 다른 협력자들완전한